聚焦临床流式领域，碧迪医疗与迈瑞医疗达成重要合作

广州日报03-04

近日，碧迪医疗生物科学与迈瑞医疗体外诊断事业部宣布正式达成重要合作。双方将聚焦临床流式领域，展开全面且深入的渠道合作，并共同为未来进一步深化品牌合作筑牢基础，携手推进中国流式业务及智慧检验整体解决方案高质量发展。　　流式细胞术作为现代免疫学诊断、血液病精准分型及肿瘤监测的核心技术，在临床诊疗中发挥着不可替代的作用。然而，长期以来，国内流式市场面临高端设备依赖进口、技术应用标准化程度不足、基层...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616535160?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-04 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616535160","market":"us","top_or_hot":-1,"title":"聚焦临床流式领域，碧迪医疗与迈瑞医疗达成重要合作","media":"广州日报","content":"<div>\n<p>近日，碧迪医疗生物科学与迈瑞医疗体外诊断事业部宣布正式达成重要合作。双方将聚焦临床流式领域，展开全面且深入的渠道合作，并共同为未来进一步深化品牌合作筑牢基础，携手推进中国流式业务及智慧检验整体解决方案高质量发展。　　流式细胞术作为现代免疫学诊断、血液病精准分型及肿瘤监测的核心技术，在临床诊疗中发挥着不可替代的作用。然而，长期以来，国内流式市场面临高端设备依赖进口、技术应用标准化程度不足、基层...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603043661816396.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>聚焦临床流式领域，碧迪医疗与迈瑞医疗达成重要合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n聚焦临床流式领域，碧迪医疗与迈瑞医疗达成重要合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 17:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202603043661816396.html><strong>广州日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，碧迪医疗生物科学与迈瑞医疗体外诊断事业部宣布正式达成重要合作。双方将聚焦临床流式领域，展开全面且深入的渠道合作，并共同为未来进一步深化品牌合作筑牢基础，携手推进中国流式业务及智慧检验整体解决方案高质量发展。　　流式细胞术作为现代免疫学诊断、血液病精准分型及肿瘤监测的核心技术，在临床诊疗中发挥着不可替代的作用。然而，长期以来，国内流式市场面临高端设备依赖进口、技术应用标准化程度不足、基层...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202603043661816396.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B031J352.USD","symbol_name":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","start_time":0,"source_url":"http://finance.eastmoney.com/a/202603043661816396.html","article_id":"2616535160","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616535160","pubTimestamp":1772616908,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"近日，碧迪医疗生物科学与迈瑞医疗体外诊断事业部宣布正式达成重要合作。双方将聚焦临床流式领域，展开全面且深入的渠道合作，并共同为未来进一步深化品牌合作筑牢基础，携手推进中国流式业务及智慧检验整体解决方案高质量发展。流式细胞术作为现代免疫学诊断、血液病精准分型及肿瘤监测的核心技术，在临床诊疗中发挥着不可替代的作用。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300760":"迈瑞医疗","IE00B031J352.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1720050803.USD":"安联全方位中国股票基金","LU2153592121.USD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc USD","LU0605514214.HKD":"FIDELITY CHINA CONSUMER \"A\" (HKD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0594300179.USD":"FIDELITY CHINA CONSUMER \"A\" (USD) ACC","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE0005HP3H50.USD":"GUINNESS CHINA \"C\" (USD) ACC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0084288322.USD":"Natixis Asia Equity RD USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU2348774022.SGD":"Aberdeen Standard SICAV I - Emerging Markets Sustainable Development Equity A Acc SGD-H","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","BK4082":"医疗保健设备","IE0031814852.USD":"FSSA GREATER CHINA GROWTH \"I\" (USD) ACC","LU1979443071.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"AD\" (USDHDG) INC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","BK4588":"碎股","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1734074674.USD":"NINETY ONE GSF ASIA PACIFIC FRANCHISE \"A\"(USD) ACC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BDX":"碧迪医疗","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU2213484517.USD":"FRANKLIN TEMPLETON CHINA A-SHARES \"A\" (USD) ACC","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","BK0251":"专用设备","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU0823426308.USD":"法巴中国股票基金","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H"},"translate_title":"Focusing on the field of clinical flow, Bidi Medical and Mindray Medical reached an important cooperation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300760":1.5,"BDX":1.5},"content_text":"近日，碧迪医疗生物科学与迈瑞医疗体外诊断事业部宣布正式达成重要合作。双方将聚焦临床流式领域，展开全面且深入的渠道合作，并共同为未来进一步深化品牌合作筑牢基础，携手推进中国流式业务及智慧检验整体解决方案高质量发展。　　流式细胞术作为现代免疫学诊断、血液病精准分型及肿瘤监测的核心技术，在临床诊疗中发挥着不可替代的作用。然而，长期以来，国内流式市场面临高端设备依赖进口、技术应用标准化程度不足、基层医疗机构可及性有限等挑战。碧迪与迈瑞的强强联合，将有效整合国际先进技术平台与本土化服务优势，打破技术与市场的双重壁垒，推动高质量流式解决方案向更广阔的市场渗透。　　据了解，此次合作将依托碧迪在流式细胞术领域的技术积淀、专业人才与解决方案优势，结合迈瑞在智能化平台、本土重大项目及渠道资源上的核心竞争力，双方将在产品与数智化创新、渠道赋能与拓展、学术及品牌推广、技术支持等方面深度协同，形成“技术+平台+渠道”的三维协同效应。　　迈瑞医疗北京研究院总经理郭文恒表示，迈瑞医疗始终深耕临床一线，致力于以自动化、智能化的技术重塑流式体验，这与碧迪生物科学的技术积淀相得益彰。他强调，通过与碧迪的强强联合，能够实现资源的最大化互补，精准解决未被满足的临床痛点，以更具创新力的组合方案，共同引领流式领域迈向高质量发展的新阶段。　　碧迪医疗大中华区生物科学业务副总裁王彤指出，此次碧迪与迈瑞达成的重要合作，标志着碧迪从“植根中国，服务中国(In China, For China)”到与中国市场的深度融合（with China）的战略决心。他强调，在流式领域，还有大量临床需求尚未被满足，通过两大头部品牌的优势互补，将有可能进一步推动中国流式技术的发展和可及性，形成一股行业发展的全新动能。（文章来源：广州日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616535160","isCrawlerRequest":true}